TY-3659

TY-3659 is a potent, allosteric, and pan-mutant selective PI3Kα inhibitor and degrader developed by TYK Medicines. It is designed to selectively target common PIK3CA hotspot mutations, including H1047R, E542K, and E545K, while sparing wild-type PI3Kα. This selectivity is intended to enhance antitumor efficacy and mitigate the metabolic toxicities, such as hyperglycemia, typically associated with wild-type PI3Kα inhibition. Preclinical studies have demonstrated that TY-3659 effectively inhibits AKT phosphorylation and induces the degradation of mutant PI3Kα proteins in various cancer cell lines (e.g., T47D, HCC1954, and MCF7). In vivo, the compound has shown potent tumor-inhibitory activity in CDX models and a favorable safety profile with no observed effects on fasting plasma glucose levels.